Related Experiment Video
Updated: Aug 3, 2025
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Mechanism of Resistance to the WDR5 Inhibitor in MLL-Rearranged Leukemia
Lulu Liu1, Lingling Shen1, Zhilou Ding2
1Novartis Institutes for BioMedical Research, 181 Massachusetts Ave., Cambridge, Massachusetts 02139, United States.
Abstract:
Drug resistance is a major problem often limiting the long-term effectiveness of targeted cancer therapeutics. Resistance can be acquired through mutations or amplification of the primary drug targets or activation of bypass signaling pathways. Considering the multifaceted function of WDR5 in human malignancies, WDR5 has emerged as an attractive drug target for the discovery of small-molecule inhibitors. In this study, we investigated if cancer cells might develop resistance to a highly potent WDR5 inhibitor. We established a drug-adapted cancer cell line and discovered that WDR5P173L mutation occurs in the resistant cells, which confers resistance by preventing target engagement of the inhibitor. This work elucidated the WDR5 inhibitor's potential resistance mechanism in a preclinical study as a reference for future study in the clinical stage.
Insights
Cancer cells can develop resistance to WDR5 inhibitors through a specific mutation (WDR5P173L). This mutation prevents the drug from binding to its target, highlighting a key resistance mechanism for future clinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Drug resistance limits the efficacy of targeted cancer therapies.
- WDR5 is a crucial protein in human cancers and a target for novel therapeutics.
- Understanding resistance mechanisms is vital for developing effective cancer treatments.
Purpose of the Study:
- To investigate potential resistance mechanisms in cancer cells treated with a WDR5 inhibitor.
- To identify genetic alterations conferring resistance to WDR5-targeted therapy.
Main Methods:
- Development of a drug-adapted cancer cell line resistant to a WDR5 inhibitor.
- Genetic analysis to identify mutations in the resistant cell line.
Main Results:
- A novel WDR5P173L mutation was identified in the drug-resistant cancer cells.
- This mutation was shown to confer resistance by blocking the inhibitor's binding to WDR5.
- The identified mutation provides a preclinical model for studying WDR5 inhibitor resistance.
Conclusions:
- The WDR5P173L mutation is a key mechanism of acquired resistance to WDR5 inhibitors.
- This finding has implications for the clinical application of WDR5-targeted cancer therapies.
- Further preclinical and clinical studies are warranted to address this resistance mechanism.
Related Concept Videos
02:56Treatment Resistant Cancers
02:23Abnormal Proliferation